Ring chromosome 17 syndrome

Ring chromosome 17 syndrome (also known as r(17) syndrome) is an extremely rare chromosomal disorder in which one copy of chromosome 17 forms a ring structure instead of its normal linear shape. This ring formation occurs when both ends of the chromosome break and rejoin, typically resulting in loss of genetic material from one or both ends. Because chromosome 17 harbors many important genes — including the tumor suppressor gene TP53 (located at 17p13.1) and the NF1 gene (at 17q11.2) — the clinical consequences can be significant and variable depending on the extent of deleted material. The syndrome primarily affects the nervous system, growth, and development. Key clinical features commonly reported include intellectual disability of variable severity, seizures (which may be difficult to control), growth retardation leading to short stature, microcephaly, café-au-lait spots, and dysmorphic facial features. Some patients may exhibit features overlapping with neurofibromatosis type 1 (NF1) when the NF1 gene region is lost, and there may be an increased predisposition to certain tumors if TP53 is deleted. Additional findings can include hypotonia, behavioral difficulties, and minor skeletal anomalies. There is no cure for ring chromosome 17 syndrome, and management is supportive and symptom-based. Treatment typically involves antiepileptic medications for seizure control, developmental therapies (speech, occupational, and physical therapy), and regular monitoring for potential tumor development. Genetic counseling is recommended for affected families. Ring chromosomes are inherently unstable during cell division, which can lead to mosaicism — meaning some cells may have the ring chromosome while others do not — contributing to the wide variability in clinical presentation among affected individuals.

Common questions about Ring chromosome 17 syndrome